Reuters logo
BRIEF-Amicus Therapeutics announces positive preliminary data from phase 1/2 study of novel treatment paradigm for pompe disease
December 8, 2016 / 12:14 PM / 10 months ago

BRIEF-Amicus Therapeutics announces positive preliminary data from phase 1/2 study of novel treatment paradigm for pompe disease

Dec 8 (Reuters) - Amicus Therapeutics Inc

* Amicus Therapeutics announces positive preliminary data from phase 1/2 study of novel treatment paradigm for pompe disease Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below